

Supplemental Figure 2. Heterozygosity of IL-20 does not alter EAE disease progression. Ten week-old *IL-20*$^{+/-}$ mice, male and female, were actively immunized for EAE (red circle) or sham-immunized (black circle) as control (n = 10). Clinical score, body weight, highest and cumulative scores, from 7 dpi to 28 dpi were analyzed by unpaired t-test **(A-C).** Difference in clinical score and body weight, highest and cumulative scores, between actively immunized *IL-20*$^{+/-}$ mice and control showed extreme statistical significance, $p<0.0001$ (mean ± SEM clinical score: 1.14 ± 0.18 vs 0.00 ± 0.00, body weight: 20.59 ± 0.14 vs 22.28 ± 0.15, **A**) (mean ± SEM highest score: 2.95 ± 0.38 vs 0.00 ± 0.00, **B**) (mean ± SEM cumulative score: 22.50 ± 3.41 vs 0.00 ± 0.00, **C**). Disease onset of actively immunized *IL-20*$^{+/-}$ mice with neurologic symptoms (10/10, mean ± SEM: 14.20 ± 0.42) **(D)**. Analysis of percentage of survival was not deemed significant **(E)**. Results are shown as Mean ± SEM, **** = $p <0.0001$.